Table III.
Drug | Year | Therapeutic agents | Target | Vehicle | Route | Condition | Phase | Status | Sponsors | Clinical trial ID |
---|---|---|---|---|---|---|---|---|---|---|
Custirsen (OGX-011) | 2004–2010 | ASO | Clusterin | None | Intravenous injection | NSCLC | I II | Completed | Achieve Life Sciences | NCT00138658 |
2012– | III | Ongoing | NCT01630733 | |||||||
Imetelstat Sodium (GRN163L) | 2007–2011 | ASO | Telomerase | ASO-lipid conjugate | Intravenous injection | NSCLC | I | Completed | Geron Corporation | NCT00510445 |
2010–2016 | II | Completed | NCT01137968 | |||||||
MRX34 | 2013–2016 | miRNA | miR-34a | Liposome | Intravenous injection | NSCLC | I | Terminated | Mirna Therapeutics, Inc. | NCT01829971 |
TargomiRs | 2015–2017 | ASO | miR-16 | Nonliving bacterial minicells | Intravenous injection | NSCLC | I | Completed | Asbestos Diseases Research Foundation | NCT02369198 |
TPI-ASM8 | 2007–2007 | ASO | βc subunit of the IL-3, IL-5, GM-CSF receptors(TOP004) CCR3(TOP005) | None | Inhalation | Asthma | II | Terminated | Pharmaxis | NCT00402948 |
2008–2008 | II | Completed | NCT00550797 | |||||||
2009–2010 | II | Completed | NCT00822861 | |||||||
2010–2012 | II | Completed | NCT01158898 | |||||||
AIR645 | 2008–2009 | ASO | IL-4/IL-13 Receptor α chain | None | Inhalation | Asthma | I | Completed | Altair Therapeutics, Inc. | NCT00658749 |
2009–2010 | II | Completed | NCT00941577 | |||||||
SB010 | 2011–2012 | ASO | GATA-3 mRNA | None | Inhalation | Asthma | I | Completed | Sterna Biologicals GmbH & Co. KG | NCT01470911 |
2012–2012 | I | Completed | NCT01554319 | |||||||
2012–2014 | I | Completed | NCT01577953 | |||||||
2012–2015 | II | Completed | NCT01743768 | |||||||
TPI 1100 | 2009–2010 | ASO | PDE4/PDE7 | None | Inhalation | COPD | I | Withdrawn | Pharmaxis | NCT00914433 |
QR-010 | 2015–2016 | ASO | CFTR mRNA | None | Inhalation intranasal route | Cystic fibrosis | I | Completed | ProQR Therapeutics | NCT02564354 |
2015– | I b | Ongoing | NCT02532764 | |||||||
ALN-RSV01 | 2007 July–November | siRNA | RSV-N gene | None | Inhalation or intranasal route | Respiratory syncytial virus infections | II | Completed | Alnylam Pharmaceuticals | NCT00496821 |
2008–2009 | II | Completed | NCT00658086 | |||||||
2010–2012 | II | Completed | NCT01065935 |
Abbreviations: ASO antisense oligonucleotide, NSCLC non-small cell lung cancer, siRNA small interference RNA, COPD chronic obstructive pulmonary disease